BofA/Merrill Lynch Starts ProNAi Therapeutics (DNAI) at Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to BofA/Merrill Lynch Starts ProNAi Therapeutics (DNAI) at Buy

Wedbush Starts ProNAi Therapeutics (DNAI) at Outperform

August 10, 2015 7:34 AM EDT

Wedbush initiates coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Outperform rating and a price target of $36.00.

Analyst David Nierengarten commented, "DNAI is a clinical-stage biotech company developing a novel therapeutic platform based on DNA interference (DNAi). ProNAi's lead candidate, PNT2258, is a... More

Jefferies Starts ProNAi Therapeutics (DNAI) at Buy

August 10, 2015 7:04 AM EDT

Jefferies initiates coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Buy rating and a price target of $37.00.

Analyst Brian Abrahams commented, "ProNAi is developing PNT2258, a Bcl2-directed oligonucleotide, in ph.II for hematological cancers. We believe DNAI is undervalued based on 2258s... More